2025-06-03-Jefferies-梅鲁斯（MRUS）_2025年美国临床肿瘤学会（ASCO）头颈癌关键意见领袖（KOL）活动要点_8页_121kb

Equity Research Summary: Merus NV (MRUS)

Overview

• Rating: Buy
• Price Target: $87.00, representing a 49% upside from the closing price of $58.53.
• Event: Covered at an institutional KOL event featuring Dr. Randall Kimple on June 3, 2025.

Key KOL Takeaways from ASCO'25

• KOL evaluates BCAX's efficacy in head and neck cancer (HNSCC), noting a 61% 1-year overall survival (OS) rate, which was below expectations but showed promise with its unique mechanism of action (MoA).
  • Interim objective response rate (ORR) under accelerated approval is deemed sufficient for broad market adoption by oncologists.
• Key factors influencing drug preference (vs. competitors like pembro/ cetuximab) include a greater 2-year OS difference (>10% delta), safety/tolerability profile, and a potential 6-month market lead.
• BCAX may have faster enrollment in first-line (1L) Phase III trials (undoubtedly) compared to second-/third-line (2L/3L) due to lower screen failure and inclusion criteria (ECOG 0-1).
• Commercial adoption hinges on entrenchment of prescribing habits via accelerated approval timeline; KOL views ORR as a key driver.
• Commentary on HNSCC heterogeneity: efficacy varies by HPV status, primary recurrence site, and disease volume; ORR differences highlight applicability in CPS 1-19+ pts, broadening pembro combo potential.

Company Description

• Merus NV: Clinical-stage oncology company developing bispecific Biclonics for solid and hematological tumors, based in The Netherlands.
• Valuation: $87 price target based on Discounted Cash Flow (DCF) and probability-adjusted earnings per share (EPS), with risks including efficacy, toxicity, and competitive pressures.

Analyst Notes

• Certifications: All analyst views reflect personal insights; compensation not tied to recommendations, per Jefferies' disclosure.
• Methodology: Price target uses multiple models including growth rate, DCF, and EBITDA; price history shows recent Buy upgrades.

Risks

• Primary Risks: Efficacy, drug toxicity, competition; potential currency fluctuations affect non-US investments; market environment volatility.

Market Trends

• KOL appreciates radiopharmaceuticals over advanced ADCs for future differentiation in HNSCC treatment.